Literature DB >> 2647712

Current status of antidepressants: clinical pharmacology and therapy.

R J Baldessarini1.   

Abstract

Effective antidepressants, including imipramine and monoamine oxidase (MAO) inhibitors, were discovered serendipitously in the 1950s. Many additional agents have been introduced since then, but most are chemically or pharmacologically similar to those known for nearly four decades. Some recently introduced antidepressants offer either lesser or dissimilar side effects, but none exceeds older treatments in efficacy. Selective serotoninpotentiating agents and short-acting MAO-A inhibitors promise efficacy with greater safety. Progress is made difficult because atypical or treatment-resistant patients are more often available for study than typical patients, and because most studies must rely heavily on potentially misleading "standard drug versus new drug" comparisons. Rational development of novel or better agents is slow, in part, due to limited understanding of the biological basis of major affective disorders and some circularity in relating actions of known drugs to pathophysiologic hypotheses. Action mechanisms of antidepressants are subtle and complex: adaptive changes occur in brain monoaminergic neurotransmission following repeated administration of agents of the tricyclic antidepressant (TCA) type that may lead to net facilitation of alpha 1-adrenergic transmission. Important advances have been made in using plasma TCA levels to guide individualization of dosing, in exploring higher doses of antidepressants when ordinary doses prove ineffective, and in recognizing a broadening spectrum of possible indications for antidepressants in adults and children. These indications include panic disorder, obsessive compulsive disorder, attention deficit disorder, and bulimia. Evidence for the prophylactic effects of antidepressants after the first months following recovery from an index episode of major depression is weak, and the treatment of common recurrent or chronic depression remains unsatisfactory. Gains have been made in increasing clinicians' and the general public's awareness of the common occurrence and appropriate treatment of major depression, even when the depression is associated with other medical or psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647712

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 4.  Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

5.  Detection and quantification of tricyclic antidepressants and other psychoactive drugs in urine by HPLC/MS/MS for pain management compliance testing.

Authors:  Justin L Poklis; Carl E Wolf; Ashley Goldstein; M Lauren Wolfe; Alphonse Poklis
Journal:  J Clin Lab Anal       Date:  2012-07       Impact factor: 2.352

Review 6.  Major depressive disorder in older adults: benefits and hazards of prolonged treatment.

Authors:  Breno S Diniz; Charles F Reynolds
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 3.923

Review 7.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 8.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

9.  Modelling the cost effectiveness of antidepressant treatment in primary care.

Authors:  D A Revicki; R E Brown; W Palmer; D Bakish; W W Rosser; S F Anton; D Feeny
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

10.  Effects of exercise and weight loss on depressive symptoms among men and women with hypertension.

Authors:  Patrick J Smith; James A Blumenthal; Michael A Babyak; Anastasia Georgiades; Alan Hinderliter; Andrew Sherwood
Journal:  J Psychosom Res       Date:  2007-11       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.